• 지역사회간호학회지
• /
• 제7권1호
• /
• pp.138-153
• /
• 1996

Intending to offer basic information for a prospective health services in Korea, this study is to investigate the complication caused by sterilization in goverment family planning program from 1962 to 1995. The results are as follows: 1. Total number of sterilization performed during the period from 1962 to 1995 were 1.367,772 cases of male sterilization and 2,889,635 cases of female sterilization. 2. Incidence of the complication caused by sterilization operation from 1980 to 1995 were 1,883(0.20%) out of 925,801 cases in vasectomies and 15,866(0.70%) out of 2,256,020 cases in tubal sterilizations. 3. Major complications in vasectomy were epididymities of 658 cases (34.9%), vas recanalization of 326 cases(17.3%), hematoma of 266 cases(14.1%), scrotal abscess of 184 cases(9.8%), sperm granuloma of 76 cases(4.0%),and other of 373 cases(19.8%). On the other hand, in tubal sterilization, ectopic pregnancy was the most significant complication of 15,078 cases (95.0%) among 15,866 total complications, followed by pelvic inflammatory diseases of 155 cases(0.9%), peritonities of 96 cases(0.6%), ovarian & tubal bleeding of 31 cases(0.2%), intestinal perforation of 16 cases (0.1%), uterine bleeding of 14 cases(0.1%), uterine cervix laceration of 1 case (0.1%), and other of 271 cases(1.7%), while 161 pregnancies(0.1%) were terminated and 43 cases(0.3%) with normal delivery. 4. The occurrence rate of the complication for each period showed that most of the complication cases by vasectomy occurred in a year after the operation -the cases were 1,256 (66.7%). 254 cases(13.5%) occurred between the next year and the 2nd year, 138 cases (7.3%) between the 2nd year and the 3rd year, 73 cases(3.9%) between the 3rd year and the 4th year, 52 cases(2.8%) between the 4th year and the 5th year, 31 cases(1.6%) between the 5th year and the 6th year, 79 cases(4.2%) over the 6th year. Tubal sterilization indicated that the occurred complication cases in a year were 2,175 cases(13.7%), 2,113 cases(13.3%) occurred between the next year and the 2nd year, 2,082 cases(13.1%) between the 2nd year and the 3rd year, 2,049 cases (12. 9%) between the 3rd year and the 4th year, 1,819 cases(11.5%) between the 4th year and the 5th year, 621 cases(10.2%) between the 5th year and the 6th year, 4,007 cases(25.3%) over the 6th year. 5. For the cost of complication treatment, total \7,928,229,000 were paid as medical expenditure in which \609,438,000 for vasectomy and \7,318,791,000 for tubal sterilization. Accordingly per capita expenses were \345,000 for vasectomy and \467,000 for tubal sterilization. As the proportion of government sterilization program was decreased after 1988, that of private sterilization program would be increased. So it is recommended to set a guideline for the private sterilization program and to continue government sterilization program for the lower class.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권2호
• /
• pp.713-717
• /
• 2016

Background: To evaluate the prevalence and features of other gynecologic or surgical lesions in endometrial cancer (EMC) patients. Materials and Methods: Clinico-pathological data of EMC patients who were treated in the institution from 1995 to 2012 were collected. Data collected were age, stage of disease according to the FIGO 2009 criteria (FIGO), histopathology, tumor grade, adjuvant therapy, other gynecologic or surgical lesions, follow-up period, and living status. Results: The mean age of 396 patients was $56.7{\pm}10.64years$. Abnormal uterine bleeding was the most common presenting symptom (90.1%). Bleeding was accompanied with pelvic mass in 7.7% and 5.4% had only a pelvic mass. Abnormal cervical cytology was found in 3.8%. Approximately 75% had early stage diseases and 86% had endometrioid histology. We found 55.8% of EMC patients had other gynecologic lesions: 89.6% benign and 9.5% malignant. Some 4.5% had pre-invasive cervical/vulva/vagina lesions. The two most common gynecologic lesions were myoma uteri and ovarian tumors. Focusing on the latter, approximately 14% were benign while 8% were malignant. Among 364 patients with available data, surgical lesions were found in 11.8%, 5.7% benign and 9.2% malignant. The most common benign surgical condition was chronic appendicitis while breast and colon cancers were the two most common malignant lesions found. Conclusions: More than half of EMC patients had other gynecologic lesions including benign and malignant tumors. Surgical lesions were also found in more than one-tenth of patients. Careful pre-operative evaluation and intra-operative inspection are advised for proper management and better prognosis.

• 셀메드
• /
• 제13권14호
• /
• pp.19.1-19.16
• /
• 2023

Objectives: To compare the efficacy of polyherbal Unani formulations in heavy menstrual bleeding due to endometrial hyperplasia. Methodology: A prospective, randomized comparative trial was conducted at Govt. Nizamia Tibbi College. Group A (n=20) received Itrifal Aftimoon 5g orally BID from menstruation day 3 to day 21 plus suprapubic Marham Dakhilyun application and per vaginally Marham Dakhilyun (5g) and Roghan Gul (10ml) application from menstruation day 5 to day 14. Group B (n=20) received Gulnar Farsi (2g), Phitakri Biryan (0.25g), Dammul Aqwain (0.25g), and Geru (2g), 2.5g powder orally BID, menstruation day 3 for 20 days plus Douche Bargh Sambhalu then Ḥamūl of Safuf Mazu (2g), Kalijiri (2g) and Roghan Gul (10ml) from menstruation day 3 to day 12 for 3 consecutive cycles. The primary outcome was pelvic ultrasound findings of endometrial thickness. The secondary outcome measures were improvement in haemoglobin percentage, change in menstrual flow and menstrual pattern. The level of significance was 5%. Results and conclusion: The intragroup comparison showed that the mean endometrial thickness at baseline and after treatment in groups A and B was extremely significantly different (P<0.0001). The intragroup comparison showed the mean haemoglobin percent at baseline and after treatment in group, A was significantly different (P<0.0001). After treatment, 50% and 60% of participants had normal duration and menstrual blood loss after treatment from baseline in Groups A and B respectively. However, further, phase II and III randomized standard controlled trials in larger samples are recommended to assess the efficacy of these group medicines.

• Clinical and Experimental Reproductive Medicine
• /
• 제51권2호
• /
• pp.151-157
• /
• 2024

Objective: People vaccinated with the coronavirus disease 2019 (COVID-19) (severe acute respiratory syndrome coronavirus-2 [SARS-CoV-2]) mRNA vaccine have reported experiencing various adverse effects. For instance, reproductive-age women have presented with complaints of abnormal uterine bleeding or menstrual cycle changes. We speculated that differences in basal sex hormone levels before and after vaccination may be present in women who experienced irregular bleeding or menstrual cycle changes; thus, this study aimed to investigate the differences in basal sex hormone levels of women before and after two doses of SARS-CoV-2 mRNA vaccination. Methods: This retrospective study included patients who received SARS-CoV-2 mRNA vaccines between January 2021 and February 2022 at a single center. In an outpatient setting, patients were queried regarding their menstrual cycle, the date of SARS-CoV-2 mRNA vaccination, vaccination type, and vaccination side effects. Differences in basal hormone levels (menstrual cycle days 2-3, follicle-stimulating hormone [FSH], luteinizing hormone [LH], and estradiol) before and after vaccination were compared. Results: Among the 326 patients, patients with no laboratory records of the hormones were excluded. The median time interval between SARS-CoV-2 mRNA vaccination and the laboratory test day was 79 days (interquartile range, 44 to 127). A comparative analysis of these hormones before and after vaccination revealed no significant differences. Subgroup analyses based on age and reported adverse events also found no statistically significant differences. Conclusion: This study showed no significant differences in basal hormone levels (FSH, LH, and estradiol) before and after SARS-CoV-2 mRNA vaccination.

• Journal of Chest Surgery
• /
• 제41권4호
• /
• pp.430-438
• /
• 2008

배경: 기계 심장판막 대치술 후 발생하는 혈전성 합병증을 방지하기 위해 항응고제 치료로써 와파린을 환자에게 투여한다. 이때 환자에 따른 적절한 와파린 용량을 결정하기 위한 지표로서 INR을 참고하는데 통상 대동맥판막은 $2.0{\sim}3.0$, 승모판막은 $2.5{\sim}3.5$가 참고치로서 받아들여지고 있다. 하지만 임상 경험상 대부분의 환자에서 이 수치로 유지하였을때 출혈성 합병증(비출혈, 혈뇨, 자궁출혈, 뇌출혈 등)이 빈번하게 발생하여 참고치보다 더 낮게 유지하는 경우가 많다. 이에 본원에서는 기계 심장판막 환자들을 후향적으로 조사하여 혈전성 합병증의 빈도가 낮은 적정한 INR을 알아보고자 한다. 대상 및 방법: 1984년 1월부터 2007년 2월까지 이엽성 기계 심장판막 대치술을 받고 생존한 311명의 환자를 대상으로 후향적으로 조사하였다. 대동맥판막치환 환자들(60명)은 INR $1.5{\sim}2.0$ (1군), $2.0{\sim}2.5$ (2군), 2.5 (3군) 이상의 세 군으로 나누고 승모판막치환(171명)이나 승모판막과 대동맥판막을 동시에 치환한 환자들(80명)은 INR $1.5{\sim}2.0$ (1군), $2.0{\sim}2.5$ (2군), $2.5{\sim}3.0$ (3군), 3.0 (4군) 이상의 네군으로 나누어 혈전성 합병증 발생률, 중요출혈성합병증 발생률을 조사하여 각각의 생존함수를 비교하였다. 결과: 대동맥 판막치환 환자 중 혈전성 합병증은 2명, 출혈성합병증은 4명이 발생하였고 세군의 혈전성 합병증의 생존함수의 차이는 관찰되지 않았고 출혈성 합병증의 생존곡선에서 1, 2군과 3군의 차이가 관찰되었다. 승모판막치환이나 승모판막과 대동맥판막을 동시에 치환한 환자들 중 혈전성 합병증은 13명, 출혈성 합병증은 15명이 발생하였고 네 군의 혈전성 합병증의 생존함수의 차이는 관찰되지 않았고 출혈성 합병증은 1, 2군과 3, 4군에서 차이를 보였다. 결론: 모든 판막에서 INR이 $1.5{\sim}2.5$ (1군과 2군)로 유지한 환자들이 그 이상으로 유지한 환자들보다 혈전성 합병증에서 차이를 보이지 않았고 출혈성 합병증에서 유의하게 감소하는 양상을 보여 이엽성 기계판막에서 적정한 INR은 $1.5{\sim}2.5$로 유지하는 것이 바람직하다고 판단된다.

• Radiation Oncology Journal
• /
• 제24권2호
• /
• pp.123-127
• /
• 2006

목적: 7예의 자궁경부의 유리세포암 초기 병기 환자들을 통하여 임상적 특징, 병리조직학적 소견, 치료방법 및 예후를 알아보고자 하였다. 대상 및 방법: 1993년 1월부터 2005년 12월까지 계명의대 동산의료원에서 병리조직학적으로 자궁경부암기 유리세포암으로 확인된 FIGO 병기 IB 6예와 IIA환자 1예, 모두 7예의 환자를 대상으로 하였으며 이들 중 1예의 IB 환자에서는 자궁 내 임신 22주 상태였다. 환자들의 의무기록을 통하여 임상적 특징, 병리조직학적 소견, 치료방법 및 예후를 분석하였다. 진단은 병리조직학적으로 유리세포암의 특징적 소견을 보이는 세포들로 50% 이상 구성되어있을 때 유리세포암으로 진단하였다. FIGO 임상병기 IB인 6명의 환자에서 근치적 자궁절제술 및 양측 골반 림프절 절제술을 시행하였으며 이들 중 2명은 수술 후 동시 항암화학방사선요법을 받았다. 1예의 IIA 환자는 동시 항암화학방사선요법으로 근치적 방사선치료를 시행하였다. 결과: 조직학적으로 자궁경부암으로 진단 받은 전체 환자 3,745명 중 유리세포암 환자는 7명이었다(0.2%). 7예의 자궁경부 유리세포암 환자의 평균 연령은 44세였으며, 연령 분포는 35세에서 53세까지였다. 가장 흔한 증상은 질 출혈로 7예 중 5예에서 나타났다(86%). 치료 전 시행한 펀치 생검 소견으로 전체 7예에서 2예에서만 유리세포암으로 진단 가능하였으며, 나머지 5예는 선편평상피세포암 1예, 미분화 선암 2예, 편평상피세포암 2예로 진단되었으나, 수술 후 병리조직학적 검사에서 유리세포암으로 확진되었다. 추적관찰기간은 13개월에서 150개월이며, 평균 추적기간은 73개월로 모두 무병상태로 생존하고 있다. 결론: 자궁경부의 유리세포암은 비록 공격적이고 악성도가 높은 종양이지만, 초기 암 환자는 정확한 병기평가와 근치적 수술 후 동시 항암화학방사선치료와 같은 적극적인 보조치료를 시행하면 보다 향상된 생존율을 얻을 수 있을 것으로 예상된다.

• Clinical and Experimental Reproductive Medicine
• /
• 제35권1호
• /
• pp.77-82
• /
• 2008

목 적: 질경유 초음파 유도하 고주파 자궁근종용해술의 임상적인 효과 및 안정성에 대해 분석해 보고자 하였다. 연구방법: 2004년 12월부터 2007년 3월사이에 질경유 초음파 유도하 고주파 자궁근종용해술을 시행받은 109명을 대상으로 하였다. 환자의 평균나이는 $42.8{\pm}5.8$세였고 모두 자궁을 보존하기 원하였다. 시술 전에 이학적 검사와 초음파를 이용한 병변의 크기 측정이 이루어졌다. 추적검사는 시술 후 1주일, 1개월, 3개월, 6개월 후 시행되었으며 동일 의사에 의해 크기 및 부피변화를 측정하였고, 방문 때마다 생리과다, 생리통 등의 근종 특이증상의 호전 유무를 추적 관찰하였다. 결 과: 근종의 평균 최대직경은 $6.1{\pm}0.5\;cm$ 이었고, 고주파용해술에 소요된 시간은 평균 $16.3{\pm}8.5$분이었다. 유의 할만한 크기와 부피의 감소는 시술 1개월 이후부터 발생하였으며 근종의 평균 최대직경은 시술 후 1주일, 1개월, 3개월, 6개월에 각각 $29.9{\pm}4.8%$ (p<0.001), $41.5{\pm}1.5%$ (p=0.05), $46.2{\pm}3.9%$ (p=0.003), $54.6{\pm}6.1%$ (p<0.001)의 감소율을 보였으며 평균 부피는 각각 $44.4{\pm}8.3%$ (p=0.001), $68.1{\pm}4.2%$ (p=0.035), $73.9{\pm}4.8%$ (p=0.042), $84.5{\pm}5.1%$ (p<0.001)의 부피 감소를 보였다. 일시적인 하복통과 출혈의 지속이 각각 3명씩 있었으나 모두 교정되었고 위중한 합병증은 발생되지 않았다. 생리통과 생리과다 등의 증상은 시술 3개월 후 유의하게 감소하였다. 결 론: 질경유 고주파 자궁근종용해술은 자궁을 보존하면서 좋은 효과와 조기 회복이 가능한 안전하고 효과적인 시술법이다.

• 여성건강간호학회지
• /
• 제10권3호
• /
• pp.226-234
• /
• 2004

Purpose: This study was to examine health status, reproductive health problems and the degree of prenatal management in working women. Method: The subjects were 902 married working women among 2,000 women selected by cluster sampling. The work area was classified to product factory, school, office, etc. After an Informed consent was obtained, participants were asked to fill out a self-administered questionnaire. The instruments included a questionnaire, parity check list, menstrual problems and gynecologic problem check list. Result: Many women have experienced menstrual cycle change during the past year. There was a significant difference in general health, menstrual regularity, reproductive health and prenatal management by occupation type. 40.6 percent of the subjects have gynecological problems such as menstrual cycle change, perineal inflammation, irregular vaginal bleeding, amenorrhea, ovarian/uterine disease, infertility, or abortion. Prenatal care was received in only 28.5% of the total subjects. In addition, 16.3% answered they had experienced low birth weight babies. Conclusion: We can conclude that working woman have changes in menstruation cycle and in reproductive health status. Therefore, we suggest that some occupational characteristics may affect subject's reproductive health, these should be clear and avoided as much as possible.

• 부모자녀건강학회지
• /
• 제21권1호
• /
• pp.1-10
• /
• 2018

Purpose: This study was to identify factors associated with premenstrual syndromes based on women's subjective assessment and investigate problems related to menstruation in female college students. Methods: The data was collected by questionnaires from 558 nursing students in a university in Gyeonggi, Korea. The data were analyzed with the IBM SPSS 21.0 program, using descriptive statistics, independent t-test, one-way ANOVA, multiple response and multiple logistic regression. Results: The problems related to menstruation included irregular menstrual cycle, severe dysmenorrhea, no menstruation, abnormal uterine bleeding, and menorrhagia. Influential factors on premenstrual syndrome revealed dysmenorrhea (${\beta}=.467$, p<.001), perceived stress status (very high) (${\beta}=.155$, p<.001), perceived stress status (high) (${\beta}=.119$. p=.002), perceived health status (very poor) (${\beta}=.102$, p=.006), and smoking (${\beta}=.087$, p=.016) in female college students. Conclusion: The findings suggest that active management and intervention regarding menstruation disorders and premenstrual syndrome are required.

• Journal of Hospice and Palliative Care
• /
• 제12권1호
• /
• pp.1-4
• /
• 2009

방사선치료의 목적은 완치목적 그리고 증상완화목적 두 가지로 나뉜다. 전체 암환자의 약 45%는 방사선치료를 받으며 이중 25${\sim}$30%는 증상완화목적의 치료를 받고있다. 방사선치료는 비록 생존기간의 연장에는 영향을 미치지 않으나 증상완화효과는 대단히 우수하며 임종시까지 삶의 질을 유지하는데 큰 역할을 한다. 증상완화 방사선치료의 적응증으로는 골전이에 의한 통증, 뇌전이, 척수압박으로 인한 신경학적 증상, 암으로 인한 기관지, 식도, 상대정맥 폐쇄 증상, 기관지, 비뇨생식기계 직장의 암성출혈 등이다. 이 중 골전이에 대한 치료가 가장 흔한 적응증이며 통증조절 외에 병적골절예방 및 척수압박예방의 효과를 가지며 약 70${\sim}$80%의 증상 완화효과를 나타낸다.